

# Sean P Gaine

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/5239567/sean-p-gaine-publications-by-year.pdf>

**Version:** 2024-04-26

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

97  
papers

13,242  
citations

39  
h-index

105  
g-index

105  
ext. papers

15,954  
ext. citations

7.8  
avg, IF

5.57  
L-index

#	Paper	IF	Citations
97	Progressive dyspnoea in a patient with idiopathic non-cirrhotic portal hypertension.. <i>Breathe</i> , <b>2022</b> , 18, 210168	1.8	
96	Long-Term Survival, Safety and Tolerability with Selexipag in Patients with Pulmonary Arterial Hypertension: Results from GRIPHON and its Open-Label Extension. <i>Advances in Therapy</i> , <b>2021</b> , 39, 796	4.1	4
95	The impact of comorbidities on selexipag treatment effect in patients with pulmonary arterial hypertension: insights from the GRIPHON study. <i>European Journal of Heart Failure</i> , <b>2021</b> ,	12.3	1
94	"It is the fear of exercise that stops me" - attitudes and dimensions influencing physical activity in pulmonary hypertension patients. <i>Pulmonary Circulation</i> , <b>2021</b> , 11, 20458940211056509	2.7	0
93	An interesting case of progressive dyspnoea and diffuse mediastinal adenopathy in a 25-year-old man. <i>Breathe</i> , <b>2021</b> , 17, 200289	1.8	
92	Perioperative management of patients with pulmonary hypertension undergoing non-cardiothoracic, non-obstetric surgery: a systematic review and expert consensus statement. <i>British Journal of Anaesthesia</i> , <b>2021</b> , 126, 774-790	5.4	6
91	Pulmonary hypertension and home-based (PHAHB) exercise intervention: protocol for a feasibility study. <i>BMJ Open</i> , <b>2021</b> , 11, e045460	3	1
90	Platelets, extracellular vesicles and coagulation in pulmonary arterial hypertension. <i>Pulmonary Circulation</i> , <b>2021</b> , 11, 20458940211021036	2.7	2
89	Routine Hematological Parameters May Be Predictors of COVID-19 Severity. <i>Frontiers in Medicine</i> , <b>2021</b> , 8, 682843	4.9	2
88	Riociguat treatment in patients with chronic thromboembolic pulmonary hypertension: Final safety data from the EXPERT registry. <i>Respiratory Medicine</i> , <b>2021</b> , 178, 106220	4.6	10
87	COVID-19 induces a hyperactive phenotype in circulating platelets. <i>PLoS Biology</i> , <b>2021</b> , 19, e3001109	9.7	42
86	Relationship Between Time From Diagnosis and Morbidity/Mortality in Pulmonary Arterial Hypertension: Results From the Phase III GRIPHON Study. <i>Chest</i> , <b>2021</b> , 160, 277-286	5.3	4
85	Mendelian randomisation and experimental medicine approaches to IL-6 as a drug target in PAH. <i>European Respiratory Journal</i> , <b>2021</b> ,	13.6	6
84	Characteristics of chronic thromboembolic pulmonary hypertension in Ireland. <i>Pulmonary Circulation</i> , <b>2021</b> , 11, 20458940211048703	2.7	
83	Risk assessment in pulmonary arterial hypertension: Insights from the GRIPHON study. <i>Journal of Heart and Lung Transplantation</i> , <b>2020</b> , 39, 300-309	5.8	19
82	Results of an Expert Consensus Survey on the Treatment of Pulmonary Arterial Hypertension With Oral Prostacyclin Pathway Agents. <i>Chest</i> , <b>2020</b> , 157, 955-965	5.3	14
81	ETNA VTE Europe: A contemporary snapshot of patients treated with edoxaban in clinical practice across eight European countries. <i>European Journal of Internal Medicine</i> , <b>2020</b> , 82, 48-55	3.9	4

80	ETNA-VTE Europe: Benefits and risks of venous thromboembolism treatment using edoxaban in the first 3 months. <i>Thrombosis Research</i> , <b>2020</b> , 196, 297-304	8.2	2
79	2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS). <i>European Heart Journal</i> , <b>2020</b> , 41, 543-603	9.5	1043
78	Idiopathic pulmonary arterial hypertension and co-existing lung disease: is this a new phenotype?. <i>Pulmonary Circulation</i> , <b>2020</b> , 10, 2045894020914851	2.7	8
77	Riociguat treatment in patients with pulmonary arterial hypertension: Final safety data from the EXPERT registry. <i>Respiratory Medicine</i> , <b>2020</b> , 177, 106241	4.6	4
76	Association of N-Terminal Pro Brain Natriuretic Peptide and Long-Term Outcome in Patients With Pulmonary Arterial Hypertension. <i>Circulation</i> , <b>2019</b> , 139, 2440-2450	16.7	32
75	ERS statement on exercise training and rehabilitation in patients with severe chronic pulmonary hypertension. <i>European Respiratory Journal</i> , <b>2019</b> , 53,	13.6	63
74	Selexipag treatment for pulmonary arterial hypertension associated with congenital heart disease after defect correction: insights from the randomised controlled GRIPHON study. <i>European Journal of Heart Failure</i> , <b>2019</b> , 21, 352-359	12.3	26
73	Pulmonary hypertension in chronic lung disease and hypoxia. <i>European Respiratory Journal</i> , <b>2019</b> , 53,	13.6	231
72	Pulmonary Arterial Hypertension-Related Morbidity Is Prognostic for Mortality. <i>Journal of the American College of Cardiology</i> , <b>2018</b> , 71, 752-763	15.1	50
71	Targeting the Prostacyclin Pathway with Selexipag in Patients with Pulmonary Arterial Hypertension Receiving Double Combination Therapy: Insights from the Randomized Controlled GRIPHON Study. <i>American Journal of Cardiovascular Drugs</i> , <b>2018</b> , 18, 37-47	4	39
70	Design and rationale of the non-interventional, edoxaban treatment in routine clinical practice in patients with venous thromboembolism in Europe (ETNA-VTE-Europe) study. <i>Thrombosis Journal</i> , <b>2018</b> , 16, 9	5.6	11
69	Temporary treatment interruptions with oral selexipag in pulmonary arterial hypertension: Insights from the Prostacyclin (PGI) Receptor Agonist in Pulmonary Arterial Hypertension (GRIPHON) study. <i>Journal of Heart and Lung Transplantation</i> , <b>2018</b> , 37, 401-408	5.8	12
68	Clinical trial protocol for TRANSFORM-UK: A therapeutic open-label study of tocilizumab in the treatment of pulmonary arterial hypertension. <i>Pulmonary Circulation</i> , <b>2018</b> , 8, 2045893217735820	2.7	49
67	Survival in portopulmonary hypertension: Outcomes of the United Kingdom National Pulmonary Arterial Hypertension Registry. <i>Journal of Heart and Lung Transplantation</i> , <b>2017</b> , 36, 770-779	5.8	47
66	Selexipag for the treatment of connective tissue disease-associated pulmonary arterial hypertension. <i>European Respiratory Journal</i> , <b>2017</b> , 50,	13.6	58
65	Pulmonary arterial hypertension: tailoring treatment to risk in the current era. <i>European Respiratory Review</i> , <b>2017</b> , 26,	9.8	20
64	Hypoxic pulmonary hypertension in chronic lung diseases: novel vasoconstrictor pathways. <i>Lancet Respiratory Medicine</i> , <b>2016</b> , 4, 225-36	35.1	40
63	Long-Term Outcome of Patients With Chronic Thromboembolic Pulmonary Hypertension: Results From an International Prospective Registry. <i>Circulation</i> , <b>2016</b> , 133, 859-71	16.7	331

62	Beyond a single pathway: combination therapy in pulmonary arterial hypertension. <i>European Respiratory Review</i> , <b>2016</b> , 25, 408-417	9.8	38
61	Dynamic Risk Stratification of Patient Long-Term Outcome After Pulmonary Endarterectomy: Results From the United Kingdom National Cohort. <i>Circulation</i> , <b>2016</b> , 133, 1761-71	16.7	203
60	Interferon beta related pulmonary arterial hypertension; an emerging worrying entity?. <i>Multiple Sclerosis and Related Disorders</i> , <b>2015</b> , 4, 284-6	4	14
59	Elevated plasma CXCL12s associated with a poorer prognosis in pulmonary arterial hypertension. <i>PLoS ONE</i> , <b>2015</b> , 10, e0123709	3.7	19
58	Recent advances in targeting the prostacyclin pathway in pulmonary arterial hypertension. <i>European Respiratory Review</i> , <b>2015</b> , 24, 630-41	9.8	51
57	Selexipag for the Treatment of Pulmonary Arterial Hypertension. <i>New England Journal of Medicine</i> , <b>2015</b> , 373, 2522-33	59.2	521
56	Right heart and pulmonary vessels structure and function. <i>Echocardiography</i> , <b>2015</b> , 32 Suppl 1, S3-10	1.5	18
55	Diagnosis and Treatment of Pulmonary Arterial Hypertension <b>2015</b> , 4105-4133		
54	Detection of high-sensitivity troponin in outpatients with stable pulmonary hypertension identifies a subgroup at higher risk of adverse outcomes. <i>Journal of Cardiac Failure</i> , <b>2014</b> , 20, 31-7	3.3	14
53	emPHasis-10: development of a health-related quality of life measure in pulmonary hypertension. <i>European Respiratory Journal</i> , <b>2014</b> , 43, 1106-13	13.6	82
52	Diagnosis and Treatment of Pulmonary Arterial Hypertension <b>2014</b> , 1-33		
51	Percutaneous atrial septostomy with modified butterfly stent and intracardiac echocardiographic guidance in a patient with syncope and refractory pulmonary arterial hypertension. <i>Heart Lung and Circulation</i> , <b>2013</b> , 22, 668-71	1.8	14
50	Elderly patients diagnosed with idiopathic pulmonary arterial hypertension: results from the COMPERA registry. <i>International Journal of Cardiology</i> , <b>2013</b> , 168, 871-80	3.2	231
49	Pulmonary Vascular Disease <b>2013</b> , 603-625		1
48	Management of pulmonary arterial hypertension. <i>Current Opinion in Critical Care</i> , <b>2013</b> , 19, 44-50	3.5	7
47	The need to move from 6-minute walk distance to outcome trials in pulmonary arterial hypertension. <i>European Respiratory Review</i> , <b>2013</b> , 22, 487-94	9.8	30
46	Medical Treatment of Pulmonary Arterial Hypertension. <i>Progress in Respiratory Research</i> , <b>2012</b> , 237-245		
45	A role for the CXCL12 receptor, CXCR7, in the pathogenesis of human pulmonary vascular disease. <i>European Respiratory Journal</i> , <b>2012</b> , 39, 1415-24	13.6	40

44	Changing demographics, epidemiology, and survival of incident pulmonary arterial hypertension: results from the pulmonary hypertension registry of the United Kingdom and Ireland. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>2012</b> , 186, 790-6	10.2	370
43	Challenges in the diagnosis and treatment of pulmonary arterial hypertension. <i>European Respiratory Review</i> , <b>2012</b> , 21, 313-20	9.8	35
42	Chronic thromboembolic disease and necrotizing granulomatous vasculitis [A case report]. <i>Respiratory Medicine CME</i> , <b>2011</b> , 4, 149-150		
41	Corrigendum to: 'Guidelines for the diagnosis and treatment of pulmonary hypertension' [European Heart Journal (2009) 30, 2493-2537]. The Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation	9.5	3
40	Chronic thromboembolic pulmonary hypertension (CTEPH): results from an international prospective registry. <i>Circulation</i> , <b>2011</b> , 124, 1973-81	16.7	630
39	Role of gremlin in the lung: development and disease. <i>American Journal of Respiratory Cell and Molecular Biology</i> , <b>2010</b> , 42, 517-23	5.7	55
38	Relief of chronic neuropathic pain through endothelin antagonism. <i>American Journal of Medicine</i> , <b>2010</b> , 123, e7	2.4	3
37	Guidelines for the diagnosis and treatment of pulmonary hypertension. <i>European Respiratory Journal</i> , <b>2009</b> , 34, 1219-63	13.6	919
36	Medical treatment of pulmonary arterial hypertension. <i>Seminars in Respiratory and Critical Care Medicine</i> , <b>2009</b> , 30, 484-92	3.9	6
35	Guidelines for the diagnosis and treatment of pulmonary hypertension: the Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT). <i>European Heart Journal</i> , <b>2009</b> , 30, 2493-537	9.5	2531
34	End points and clinical trial design in pulmonary arterial hypertension. <i>Journal of the American College of Cardiology</i> , <b>2009</b> , 54, S97-S107	15.1	166
33	Updated clinical classification of pulmonary hypertension. <i>Journal of the American College of Cardiology</i> , <b>2009</b> , 54, S43-S54	15.1	1640
32	Guía de práctica clínica para el diagnóstico y tratamiento de la hipertensión pulmonar. <i>Revista Espanola De Cardiologia (English Ed)</i> , <b>2009</b> , 62, 1464.e1-1464.e58	0.7	1
31	Guía de práctica clínica para el diagnóstico y tratamiento de la hipertensión pulmonar. <i>Revista Espanola De Cardiologia</i> , <b>2009</b> , 62, 1464.e1-1464.e58	1.5	3
30	Lung-selective gene responses to alveolar hypoxia: potential role for the bone morphogenetic antagonist gremlin in pulmonary hypertension. <i>American Journal of Physiology - Lung Cellular and Molecular Physiology</i> , <b>2008</b> , 295, L272-84	5.8	67
29	Poor outcomes associated with drainage of pericardial effusions in patients with pulmonary arterial hypertension. <i>Southern Medical Journal</i> , <b>2008</b> , 101, 490-4	0.6	43
28	Combination therapy and new types of agents for pulmonary arterial hypertension. <i>Clinics in Chest Medicine</i> , <b>2007</b> , 28, 169-85, ix	5.3	41
27	Migraine with aura following atrial septostomy for pulmonary arterial hypertension. <i>Nature Clinical Practice Cardiovascular Medicine</i> , <b>2007</b> , 4, 55-8		6

26	Temporal trends and drug exposures in pulmonary hypertension: an American experience. <i>American Heart Journal</i> , <b>2006</b> , 152, 521-6	4.9	65
25	Pulmonary Vascular Disease <b>2005</b> , 661-680		
24	Bosentan: a novel agent for the treatment of pulmonary arterial hypertension. <i>International Journal of Clinical Practice</i> , <b>2004</b> , 58, 69-73	2.9	11
23	Diagnosis and differential assessment of pulmonary arterial hypertension. <i>Journal of the American College of Cardiology</i> , <b>2004</b> , 43, 40S-47S	15.1	651
22	Efficacy and safety of treprostinil: an epoprostenol analog for primary pulmonary hypertension. <i>Journal of Cardiovascular Pharmacology</i> , <b>2003</b> , 41, 293-9	3.1	184
21	Hepatopulmonary syndromes: treatment of liver transplantation candidates. <i>Current Opinion in Organ Transplantation</i> , <b>2002</b> , 7, 107-113	2.5	2
20	Primary pulmonary hypertension is not associated with scleroderma-like changes in nailfold capillaries. <i>Chest</i> , <b>2001</b> , 120, 796-800	5.3	18
19	Liver transplantation in patients with severe portopulmonary hypertension treated with preoperative chronic intravenous epoprostenol. <i>Liver Transplantation</i> , <b>2001</b> , 7, 745-9	4.5	54
18	Increased levels of prostaglandin D(2) suggest macrophage activation in patients with primary pulmonary hypertension. <i>Chest</i> , <b>2001</b> , 120, 1639-44	5.3	23
17	Lung transplantation for pulmonary hypertension. <i>Seminars in Respiratory and Critical Care Medicine</i> , <b>2001</b> , 22, 533-40	3.9	1
16	Epoprostenol for treatment of pulmonary hypertension in patients with systemic lupus erythematosus. <i>Chest</i> , <b>2000</b> , 117, 14-8	5.3	91
15	Pulmonary hypertension. <i>JAMA - Journal of the American Medical Association</i> , <b>2000</b> , 284, 3160-8	27.4	111
14	Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized, controlled trial. <i>Annals of Internal Medicine</i> , <b>2000</b> , 132, 425-34	8	710
13	Anastomotic pulmonary hypertension after lung transplantation for primary pulmonary hypertension: report of surgical correction. <i>Chest</i> , <b>1999</b> , 116, 564-6	5.3	11
12	Continuous intravenous epoprostenol therapy for pulmonary hypertension in Gaucher's disease. <i>Chest</i> , <b>1999</b> , 116, 1127-9	5.3	18
11	Induction of heme oxygenase-1 with hemoglobin depresses vasoreactivity in rat aorta. <i>Journal of Vascular Research</i> , <b>1999</b> , 36, 114-9	1.9	11
10	Pulmonary vascular endothelial responses are differentially modulated after cardiopulmonary bypass. <i>Journal of Cardiovascular Pharmacology</i> , <b>1999</b> , 34, 518-25	3.1	7
9	Portopulmonary hypertension and the liver transplant candidate. <i>Transplantation</i> , <b>1999</b> , 67, 1087-93	1.8	100

8	Short-term outcome and predictors of adverse events following pulmonary thromboendarterectomy. <i>World Journal of Surgery</i> , <b>1998</b> , 22, 1029-32; discussion 1033	3.3	25
7	Action of fenfluramine on voltage-gated K <sup>+</sup> channels in human pulmonary-artery smooth-muscle cells. <i>Lancet, The</i> , <b>1998</b> , 352, 290	4.0	34
6	Attenuated K <sup>+</sup> channel gene transcription in primary pulmonary hypertension. <i>Lancet, The</i> , <b>1998</b> , 351, 726-7	4.0	234
5	Primary pulmonary hypertension. <i>Lancet, The</i> , <b>1998</b> , 352, 719-25	4.0	425
4	Dysfunctional voltage-gated K <sup>+</sup> channels in pulmonary artery smooth muscle cells of patients with primary pulmonary hypertension. <i>Circulation</i> , <b>1998</b> , 98, 1400-6	16.7	343
3	Medical and surgical treatment options for pulmonary hypertension. <i>American Journal of the Medical Sciences</i> , <b>1998</b> , 315, 179-84	2.2	18
2	Successful use of chronic epoprostenol as a bridge to liver transplantation in severe portopulmonary hypertension. <i>Transplantation</i> , <b>1998</b> , 65, 457-9	1.8	87
1	What is the clinical course of patients hospitalised for COVID-19 treatment Ireland: a retrospective cohort study in Dublin's North Inner City (the Mater 100)		3